OTC · Healthcare
Zomedica Corp. (ZOMDF)
As-reported financials and recent SEC filings for Zomedica Corp., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$32.0M
Net income
$-81.9M
Net margin
—
Diluted EPS
$-0.08
ROE
-70.9%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $32.0M | $27.3M | $25.2M | $18.9M | $4.1M |
| Gross profit | $21.7M | $19.1M | $17.3M | $13.5M | $3.1M |
| Operating income | $-84.4M | $-51.1M | $-43.3M | $-21.9M | $-21.4M |
| Net income | $-81.9M | $-47.0M | $-34.5M | $-17.0M | $-18.4M |
| Diluted EPS | $-0.08 | $-0.05 | $-0.04 | $-0.02 | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-11
View on EDGAR →42026-05-26
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-14
View on EDGAR →42026-05-11
View on EDGAR →42026-05-08
View on EDGAR →8-K2026-05-06
View on EDGAR →Largest Healthcare peers
Go deeper on ZOMDF
Search Zomedica Corp.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.